Key Takeaways

  • In a 1,880-person trial, stopping statins after 70 met the researchers' two-year safety bar for people who had never had cardiovascular disease
  • Over the full follow-up, heart attacks, strokes or deaths occurred in 12.7% of those who stopped versus 9.2% of those who continued
  • The trial covered primary prevention only — it says nothing about stopping statins after a heart attack or stroke

Should a healthy 75-year-old still be taking a statin "just in case"?

Millions of older adults take a statin every day even though they have never had a heart attack or a stroke — prescribed years ago to lower cholesterol and, with it, future risk. Whether they should ever stop is a question doctors have mostly had to guess at. A major trial published in the New England Journal of Medicine this month finally tested it.

The STREAM trial randomly assigned 1,880 adults aged 70 and older — average age 77.5, all taking statins for prevention, all with at least two chronic conditions, and none with known cardiovascular disease — to either stop their statin or keep taking it.

The two-year answer: stopping cleared the bar

At two years, the group that stopped had, on average, about two fewer weeks of event-free survival than the group that continued — a difference small enough to fall inside the safety margin the researchers had set in advance. On that measure, stopping was officially "noninferior": not shown to be meaningfully worse over two years.

The longer answer is less comfortable

Followed for longer — up to four years — the gap widened. A heart attack, stroke or death occurred in 12.7% of those who stopped versus 9.2% of those who continued. Put plainly by the researchers presenting the trial: roughly one extra cardiovascular event over two years for every 40 people who stopped. The curves kept separating with time, which is why specialists discussing the trial preferred the phrase "acceptable risk" to "safe."

The trial also had limits. It was open-label — everyone knew who had stopped. And it studied people who were already tolerating statins well, not people struggling with side effects. Most importantly, it covered primary prevention only: nobody in the trial had already had a heart attack or stroke, the situation where statins' benefits are clearest.

Health note: This trial is a conversation starter, not an instruction. Stopping a prescribed statin — especially after any cardiovascular event — is a decision to make with your own doctor, who knows your full risk picture.

The Twikup Take

"Safe to stop" and "no downside to stopping" turned out to be different answers, depending on how long you watch. STREAM's real gift is precision: doctors and patients over 70 now have actual numbers to weigh, instead of a shrug.

Image: Illustrative image.

Sources